FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134996983> ?p ?o ?g. }

• W2134996983 endingPage "14" @default.
• W2134996983 startingPage "1408" @default.
• W2134996983 abstract "The antitumor activity of combination therapy with recombinant human tumor necrosis factor alpha (rhTNF-alpha), recombinant human interleukin 2 (rhIL-2), and recombinant hybrid alpha-interferon A/D (rhIFN-alpha A/D) was assessed against established weakly immunogenic (MCA-106) and nonimmunogenic (MCA-102) sarcomas at both s.c. and visceral (hepatic) sites. C57BL/6 mice were treated with a single i.v. dose of rhTNF-alpha followed by rhIL-2 (75,000 units) and rhIFN-alpha A/D (75,000 units) i.p. twice daily for 5 consecutive days. Substantial improvements were observed when the combination of rhTNF-alpha, rhIL-2, and rhIFN-alpha A/D was administered, as measured by regression of tumor, prolongation of survival, and improved cure rates, compared with any combination of two cytokines or any cytokine alone against the MCA-106 sarcoma. These findings were consistent in both the s.c. and single hepatic tumor models. For example, treatment of the MCA-106 s.c. tumor bearers with the triple cytokine combination resulted in cures of 16 of 18, 17 of 18, and 12 of 18 mice receiving rhTNF-alpha dosages of 2, 4, and 6 micrograms, respectively, compared with 2 of 18, 7 of 18, and 9 of 18 at 2, 4, and 6 micrograms of rhTNF-alpha plus rhIL-2 without rhIFN-alpha A/D. Established 10-day single liver tumor weights when treated with the triple combination therapy were 54 and 25 mg in treatment groups receiving 2 and 4 micrograms of rhTNF-alpha, compared with 376 and 302 mg with the same amounts of rhTNF-alpha alone (P less than 0.004). Mice bearing hepatic sarcomas treated with triple cytokine combination therapy had cure rates of 50% and 67% at rhTNF-alpha doses of 2 and 4 micrograms, compared with no survivors with rhTNF-alpha alone. No improved antitumor effects resulted from therapy with any cytokine alone or in combination against the nonimmunogenic MCA-102 sarcoma. Possible in vivo mechanisms by which these three cytokines synergize are discussed." @default.
• W2134996983 created "2016-06-24" @default.
• W2134996983 creator A5004554374 @default.
• W2134996983 creator A5014977535 @default.
• W2134996983 creator A5070367132 @default.
• W2134996983 creator A5072133376 @default.
• W2134996983 date "1989-03-15" @default.
• W2134996983 modified "2023-09-28" @default.
• W2134996983 title "Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice." @default.
• W2134996983 cites W1483963831 @default.
• W2134996983 cites W153538655 @default.
• W2134996983 cites W1550814250 @default.
• W2134996983 cites W1561387023 @default.
• W2134996983 cites W1577248203 @default.
• W2134996983 cites W1850012475 @default.
• W2134996983 cites W1976177466 @default.
• W2134996983 cites W1982213879 @default.
• W2134996983 cites W1985981664 @default.
• W2134996983 cites W1989783048 @default.
• W2134996983 cites W1992071813 @default.
• W2134996983 cites W2002209097 @default.
• W2134996983 cites W2012913493 @default.
• W2134996983 cites W2014113952 @default.
• W2134996983 cites W2016951403 @default.
• W2134996983 cites W2030124997 @default.
• W2134996983 cites W2046621497 @default.
• W2134996983 cites W2049822454 @default.
• W2134996983 cites W2053414650 @default.
• W2134996983 cites W2072716515 @default.
• W2134996983 cites W2086846999 @default.
• W2134996983 cites W2089828715 @default.
• W2134996983 cites W2095343750 @default.
• W2134996983 cites W2097668214 @default.
• W2134996983 cites W2130537353 @default.
• W2134996983 cites W2131546616 @default.
• W2134996983 cites W2132779751 @default.
• W2134996983 cites W2140769991 @default.
• W2134996983 cites W2150858574 @default.
• W2134996983 cites W2172109321 @default.
• W2134996983 cites W2322553446 @default.
• W2134996983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2784349" @default.
• W2134996983 hasPublicationYear "1989" @default.
• W2134996983 type Work @default.
• W2134996983 sameAs 2134996983 @default.
• W2134996983 citedByCount "21" @default.
• W2134996983 countsByYear W21349969832022 @default.
• W2134996983 crossrefType "journal-article" @default.
• W2134996983 hasAuthorship W2134996983A5004554374 @default.
• W2134996983 hasAuthorship W2134996983A5014977535 @default.
• W2134996983 hasAuthorship W2134996983A5070367132 @default.
• W2134996983 hasAuthorship W2134996983A5072133376 @default.
• W2134996983 hasConcept C104317684 @default.
• W2134996983 hasConcept C126322002 @default.
• W2134996983 hasConcept C141071460 @default.
• W2134996983 hasConcept C17991360 @default.
• W2134996983 hasConcept C203014093 @default.
• W2134996983 hasConcept C2775944032 @default.
• W2134996983 hasConcept C2776178377 @default.
• W2134996983 hasConcept C2776999253 @default.
• W2134996983 hasConcept C2777371288 @default.
• W2134996983 hasConcept C2777701055 @default.
• W2134996983 hasConcept C2778690821 @default.
• W2134996983 hasConcept C2781228144 @default.
• W2134996983 hasConcept C2909179924 @default.
• W2134996983 hasConcept C40767141 @default.
• W2134996983 hasConcept C49453240 @default.
• W2134996983 hasConcept C503630168 @default.
• W2134996983 hasConcept C55493867 @default.
• W2134996983 hasConcept C64943373 @default.
• W2134996983 hasConcept C71924100 @default.
• W2134996983 hasConcept C86803240 @default.
• W2134996983 hasConcept C8891405 @default.
• W2134996983 hasConceptScore W2134996983C104317684 @default.
• W2134996983 hasConceptScore W2134996983C126322002 @default.
• W2134996983 hasConceptScore W2134996983C141071460 @default.
• W2134996983 hasConceptScore W2134996983C17991360 @default.
• W2134996983 hasConceptScore W2134996983C203014093 @default.
• W2134996983 hasConceptScore W2134996983C2775944032 @default.
• W2134996983 hasConceptScore W2134996983C2776178377 @default.
• W2134996983 hasConceptScore W2134996983C2776999253 @default.
• W2134996983 hasConceptScore W2134996983C2777371288 @default.
• W2134996983 hasConceptScore W2134996983C2777701055 @default.
• W2134996983 hasConceptScore W2134996983C2778690821 @default.
• W2134996983 hasConceptScore W2134996983C2781228144 @default.
• W2134996983 hasConceptScore W2134996983C2909179924 @default.
• W2134996983 hasConceptScore W2134996983C40767141 @default.
• W2134996983 hasConceptScore W2134996983C49453240 @default.
• W2134996983 hasConceptScore W2134996983C503630168 @default.
• W2134996983 hasConceptScore W2134996983C55493867 @default.
• W2134996983 hasConceptScore W2134996983C64943373 @default.
• W2134996983 hasConceptScore W2134996983C71924100 @default.
• W2134996983 hasConceptScore W2134996983C86803240 @default.
• W2134996983 hasConceptScore W2134996983C8891405 @default.
• W2134996983 hasIssue "6" @default.
• W2134996983 hasLocation W21349969831 @default.
• W2134996983 hasOpenAccess W2134996983 @default.
• W2134996983 hasPrimaryLocation W21349969831 @default.
• W2134996983 hasRelatedWork W1946368585 @default.

• next